Endocrine Abstracts

42-year-old female with relapsing Graves’ disease treated with propylthiouracil (PTU) presented to the Emergency Department with a two-week history of fevers, night sweats, transient rash, arthralgia and fatigue. Five years previously she presented with Graves’ disease, TSH <0.02 mIU/l, FT4 of 39.8 pmol/l (9–16 pmol/l) and TSH receptor antibody positive with a titre of 11.3 IU/l. Initially treated with carbimazole therapy but developed an urticarial rash, lo...

Case presentation: A 35-year-old man presented to the emergency department (ED) in a confused and agitated state. His past medical history was significant for poorly controlled type 1 diabetes, complicated by background diabetic retinopathy. He was taking basal/bolus insulin and had a history of diabetic ketoacidosis (DKA) eleven years prior. He also had multiple sclerosis however disengaged with neurology services and was non-compliant with interferon therapy. Prior to admiss...

Case presentation: A 35-year-old man presented to the emergency department (ED) in a confused and agitated state. His past medical history was significant for poorly controlled type 1 diabetes, complicated by background diabetic retinopathy. He was taking basal/bolus insulin and had a history of diabetic ketoacidosis (DKA) eleven years prior. He also had multiple sclerosis however disengaged with neurology services and was non-compliant with interferon therapy. Prior to admiss...

Background: Improved survival rates from brain tumours have resulted in patients living longer with the effects of radiotherapy. Advances in conventional fractionated radiotherapy, such as intensity-modulated radiotherapy (IMRT), enable radiation to be delivered more precisely while partially sparing surrounding structures including the hypothalamic-pituitary axis. Despite these advances, the precise risk of hypopituitarism associated with IMRT in survivors of adult-onset non-...

11-oxygenated androgens are a group of adrenal-derived C19 steroids that require activation in peripheral tissues. 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) has been shown in vitro to be essential for 11-oxygenated androgen activation, converting 11β-hydroxyandrostenedione (11OHA4) to 11-ketoandrostenedione (11KA4), the direct precursor of the potent androgen 11-ketotestosterone (11KT). As the kidney is the major site of HSD11B2 expression, we hypoth...